TABLE 3.
Clinical Benefit Assessment of Paclitaxel, Carboplatin, and Reolysin in Non-Small Cell Lung Cancer
| Patient No. | Abnormality | Amino Acid | Nucleotide | Histology | Cycle No. | Best Response | PET SUV Change, % | Progression-Free Survival, d | Overall Survival, d |
|---|---|---|---|---|---|---|---|---|---|
| 0023 | KRAS, EGFR Amp | G12C | c.34G>T | Adenocarcinoma | 2 | PD | IC | 31 | 193 |
| 0004 | KRAS, EGFR Amp | G12C | c.34G>T | NSC NOS | 6 | SD | −49.8 | 120 | 1195 |
| 0006 | KRAS, EGFR Amp | G12D | c.34G>A | Adenocarcinoma | 6 | SD | ND | 119 | 690 |
| 0020 | KRAS, EGFR Amp | G12C | c.34G>T | Adenocarcinoma | 4 | SD | 1.4 | 78 | 343 |
| 0026 | KRAS, EGFR Amp | G12C | c.34G>T | NSC NOS | 8 | SD | −51.8 | 196 | 279 |
| 0027 | KRAS, EGFR Amp | G12V | c.34G>T | Adenocarcinoma | 4 | SD | −22.3 | 80 | 508 |
| 0001 | KRAS | G12R | c.34G>C | Adenocarcinoma | 3 | PR | −80.6 | 170 | 227 |
| 0002 | KRAS | G12C | c.34G>T | Adenocarcinoma | 4 | PR | ND | 624 | >2164 |
| 0007 | KRAS | G13R | c.37G>C | Adenocarcinoma | 1 | NE | ND | N/A | Unknown |
| 0013 | KRAS | G12C | c.34G>T | Adenocarcinoma | 4 | SD | ND | 80 | 96 |
| 0014 | KRAS | G13C | c.37G>T | Adenocarcinoma | 4 | SD | ND | 78 | 182 |
| 0017 | KRAS | G12C; G12V | c.34G>T; c.35G>T | Adenocarcinoma | C4D1 | SD | −64.0 | 235 | 290 |
| 0025 | KRAS | G12C | c.34G>T | Adenocarcinoma | 1 | NE | ND | 90 | 228 |
| 0028 | KRAS | G12S | c.34G>A | NSC NOS | 4 | SD | 0.0 | 88 | 172 |
| 0032 | KRAS | G12V | c.35G>T | Adenocarcinoma | 14 | PR | −48.5 | 302 | >999 |
| 0034 | KRAS | G12V | c.35G>T | Adenocarcinoma | 4 | SD | −36.3 | 80 | 175 |
| 0035 | KRAS | G12A | c.35G>C | Adenosquamous | 6 | SD | −34.5 | 120 | >828 |
| 0037 | KRAS | G12C | c.34G>T | Adenocarcinoma | 6 | PR | −0.1 | Died without PD | 216 |
| 0031 | KRAS | G12A | c.35G>C | Adenocarcinoma | 47 | PR | −100.0 | >1105 | >1105 |
| 0038 | KRAS | G12C | c.34G>T | Adenocarcinoma | 2 | PD | ND | 38 | 118 |
| 0005 | EGFRm, EGFR Amp | p.E746_T51 del | c.2237_2251del15 | Bronchioloalveolar | 6 | PR | ND | 139 | 498 |
| 0011 | EGFRm, EGFR Amp | p.E746_T51 del | c.2237_2251del15 | NSC NOS | 1 | PD | ND | 4 | 105 |
| 0018 | EGFRm | p.E746_T51 del | c.2237_2251del15 | Adenocarcinoma | C6D1 | SD | −13.9 | >1486 | >1486 |
| 0003 | EGFR Amp | Adenosquamous | 3 | SD | −37.6 | 88 | 359 | ||
| 0008 | EGFR Amp | NSC NOS | 8 | SD | ND | 170 | 589 | ||
| 0015 | EGFR Amp | Adenocarcinoma | 4 | SD | ND | 78 | 129 | ||
| 0019 | EGFR Amp | Adenocarcinoma | 10 | PR | −34.3 | 210 | 399 | ||
| 0022 | EGFR Amp | Adenocarcinoma | 6 | SD | 0.0 | 120 | 249 | ||
| 0024 | EGFR Amp | Adenocarcinoma | 6 | SD | −50.2 | 121 | 1067 | ||
| 0029 | EGFR Amp | Adenocarcinoma | 4 | PR | −63.1 | 93 | 369 | ||
| 0030 | EGFR Amp | Adenocarcinoma | 14 | SD | −18.9 | 316 | 658 | ||
| 0033 | EGFR Amp | Adenocarcinoma | 14 | SD | −30.7 | 248 | >837 | ||
| 0021 | EGFR Amp | Squamous | 8 | PR | −80.8 | 185 | 468 | ||
| 0009 | BRAF, EGFR Amp | V600E | c.1799T>A | Adenocarcinoma | 6 | SD | −34.0 | 575 | 854 |
| 0010 | BRAF, EGFR Amp | V600E | c.1799T>A | Adenocarcinoma | 2 | PD | 0.0 | 36 | 382 |
| 0012 | BRAF, EGFR Amp | V600E | c.1799T>A | Adenocarcinoma | 4 | PR | ND | 1460 | >1850 |
| 0016 | BRAF, EGFR Amp | V600E | c.1799T>A | NSC NOS | 8 | PR | −91.3 | 168 | 803 |
Abbreviations: Amp, amplified; C4D1, cycle 4 day 1; C6D1, cycle 6 day 1; EGFR, epidermal growth factor receptor; EGFRm, EGFR mutated; IC, incomplete; N/A, not available; ND, not determined; NE, not evaluable; NOS, not otherwise specified; NSC, non-small cell; PD, progressive disease; PET, positron emission tomography; PR, partial response; SD, stable disease; SUV, standardized uptake value.